Claims
- 1. A method for detecting a pathological cell in a patient, said method comprising detecting in a biological sample from said patient a nucleic acid or polypeptide comprising a sequence at least 80% identical to a sequence selected from SEQ ID NOs:1-116.
- 2. The method of claim 1, wherein said pathological cell has a pathology selected from those listed Table 1.
- 3. The method of claim 1, wherein said biological sample is tissue from an organ which is affected by a pathology listed in Table 1.
- 4. The method of claim 1, wherein said nucleic acids are mRNA.
- 5. The method of claim 1, further comprising a step of amplifying nucleic acids.
- 6. The method of claim 1, wherein said nucleic acid comprises a sequence selected from SEQ ID NOs:1-58.
- 7. The method of claim 1, wherein said polypeptide comprises a sequence selected from SEQ ID NOs:59-116.
- 8. The method of claim 1, wherein said detecting comprises using a biochip comprising a nucleic acid at least 80% identical to SEQ ID NOs: 1-58.
- 9. The method of claim 1, wherein said patient is undergoing a therapeutic regimen to treat a pathology selected from those listed Table 1.
- 10. The method of claim 1, wherein said patient is suspected of having a pathology selected from those listed Table 1.
- 11. An isolated nucleic acid molecule comprising a sequence selected from SEQ ID NOs:1-58.
- 12. The nucleic acid molecule of claim 11, wherein the nucleic acid is labeled.
- 13. An expression vector comprising the nucleic acid of claim 11.
- 14. A host cell comprising the expression vector of claim 13.
- 15. An isolated nucleic acid encoding a polypeptide sequence selected from SEQ ID NOs: 59-116.
- 16. An isolated polypeptide encoded by a sequence selected from SEQ ID NOs:1-58.
- 17. An antibody that specifically binds a polypeptide of claim 16.
- 18. The antibody of claim 17, wherein the antibody is a humanized antibody.
- 19. The antibody of claim 17, wherein the antibody is an antibody fragment.
- 20. The antibody of claim 17, wherein the antibody is conjugated to an effector component.
- 21. The antibody of claim 17, wherein the antibody is conjugated to a detectable label or a cytotoxic chemical.
- 22. A method for specifically targeting a compound to a pathological cell in a patient, said method comprising administering to said patient an antibody of claim 17, wherein said antibody is conjugated to the compound.
- 23. A method for detecting a pathological cell in a patient, said method comprising contacting a biological sample with an antibody of claim 17.
- 24. The method of claim 22, wherein said antibody is conjugated to an effector component or a fluorescent label.
- 25. The method of claim 22, wherein said said biological sample is a blood, serum, urine, or stool sample.
- 26. A method for identifying a compound that modulates a pathology-associated polypeptide, said method comprising:
a) contacting said compound with a pathology-associated polypeptide, said polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to SEQ ID NOs:1-58; and b) determining the effect of said compound upon the function of said polypeptide.
- 27. A screening assay comprising:
a) administering a test compound to a cell from a mammal exhibiting a pathology selected from those listed in Table 1; b) administering a test compound to a cell from a mammal not exhibiting said pathology; c) comparing the expression level of a polynucleotide of the cell comprising a sequence at least 80% identical to SEQ ID NOs:1-58 with the expression level of said polynucleotide of a control cell; whereby modulation of the expression level of the polynucleotide of the cell indicates that the test compound is a drug candidate.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application No. 60/448,784 filed Feb. 19, 2003, which is hereby incorporated by reference herein in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60448784 |
Feb 2003 |
US |